Three Times Repeated Portal Venous Gas after Meals

Takamasa Kobayashi¹, Atsunori Tsuchiya¹, Takeshi Suda² and Shuji Terai¹

Key words: portal venous gas, chronic mesenteric ischemia, capsule endoscopy

(A Intern Med 55: 843-845, 2016)

DOI: 10.2169/internalmedicine.55.6036)

A 62-year-old man was admitted due to long-shallow gastric ulcers (Picture 1). He was on various medications including warfarin. After admission, during which warfarin was stopped, he had a mild cerebral infarction, thus a heparin infusion was started (12,000 U/day). On day 20 he resumed meals and had short-term periumbilical pain. Computed tomography revealed portal venous gas (PVG) that disappeared the next day without intestinal ischemic change, and severe arteriosclerotic stenoses at both trunks of the superior- and inferior-mesenteric artery (SMA and IMA) (Picture 2). While the heparin dose was increased to 18,000 U/day, the same episode occurred two more times (Picture 3).

Since capsule endoscopy after the third PVG showed multiple ischemic areas in the distal jejunum (Picture 4; upper panels), oral administration of clopidogrel and beraprost so-

¹Department of Gastroenterology and Hepatology, Graduate School of Medical and Dental Science, Niigata University, Japan and ²Department of Gastroenterology and Hepatology, Uonuma Institute of Community Medicine, Niigata Medical and Dental Hospital, Japan

Received for publication June 24, 2015; Accepted for publication July 20, 2015
Correspondence to Dr. Atsunori Tsuchiya, atsunori@med.niigata-u.ac.jp
dium was initiated, and the attack subsequently disappeared for more than one year (Picture 4; lower-panels). These clinical findings suggested that relative ischemia of the intestine after meals caused erosions/ulcers from where intestinal gas flowed into the portal vein.

This case clearly showed a reversible “chronic mesenteric ischemia-ischemic enteritis-PVG” sequence (1, 2). Anti-platelet and anti-coagulant therapies have a dual nature. While these drugs can lead to a risk of bleeding from damaged erosions/ulcers, these drugs can also prevent/improve this mucosal damage.
Author’s disclosure of potential Conflicts of Interest (COI).
Shuji Terai: Honoraria, Otsnka Pharmaceutical.

References


© 2016 The Japanese Society of Internal Medicine
http://www.naika.or.jp/imonline/index.html